期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

可溶性白细胞分化抗原40配体对急性冠脉综合征预后评价的意义 被引量：1

Soluble CD40L in Prognosis of Acute Coronary Syndrome
下载PDF
导出
摘要 可溶性白细胞分化抗原40配体作为急性冠脉综合征时血小板活化的指标,较肌钙蛋白而言,能提供动脉粥样斑块破裂和血小板激活的更为直接的信息。具有重要的早期诊断和预测意义。大量的研究已经证实了可溶性白细胞分化抗原40配体与急性冠脉综合征的密切关系。因此,临床上,将可溶性白细胞分化抗原40配体用于对急性冠脉综合征预后的预测与评估具有重要意义。本综述阐述可溶性白细胞分化抗原40配体的来源,可溶性白细胞分化抗原40配体与急性冠脉综合征关系,以及可溶性白细胞分化抗原40配体对急性冠脉综合征预后的预测价值。 Soluble CD40 ligand（sCD40L） which is the symbol of platelet activation has provided a more direct information of atherosclerotic plaque rupture and platelet activation as compared with cardiac troponin. So it has an important value in the prognosis of acute coronary syndrome（ACS）. There are a large number of investigations that have indicated the relations between sCD40L and ACS. Therefore, sCD40L can be used in the evaluation of prognosis of acute coronary syndrome. This review expounds it＇ s origin, the relation with ACS and the value of evaluation in acute coronary syndrome.
作者 黄宇 陆纪德 邱建平
机构地区 上海浦东新区公利医院心内科
出处 《心血管病学进展》 CAS 2008年第B05期36-38,共3页 Advances in Cardiovascular Diseases
关键词 可溶性白细胞分化抗原40配体 急性冠脉综合征 预后 soluble CD40 ligand acute coronary syndrome prognosis
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献16

  • 1Garlichs CD, Eskafi S, Raaz D,et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets [J]. Heart,2001,86(6) :649- 655.
  • 2Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease [ J ]. Circulation,2002,106 ( 8 ) : 896-899.
  • 3Henn V,Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40 [ J]. Blood,2001,98(4) : 1047-1054.
  • 4Schonbeck U, Gerdes N, Varo N, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells [ J ]. Circulation, 2002,106 ( 23 ) : 2888-2893.
  • 5Nannizzi-Alaimo L,Alves VL,Prasad KS,et al. GP Ⅱb-Ⅲa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation [ J]. Circulation,2001,104( suppl Ⅱ) : Ⅱ - 318.
  • 6Schonbeck U, Sukhova GK, Shimizu K,et al. Inhibition of CD40 signaling limitsevolution of estabhshed atherosclerosis in mice [ J ]. Proc Natl Acad Sci USA, 2000,97 ( 13 ) :7458-7463.
  • 7Bavendick U, Libby P, Kibride M, et al. Induction of tissue factor expression in human endothelial ceils by CD40 ligand is mediated via activator protein 1, nuclear factor kappaB, and Egr-1 [ J ]. J Biol Chem, 2002,277 ( 28 ) : 25032- 25039.
  • 8Anne GS,Sannevan W,Thor U,et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia : downregulate effect of statin therapy[J]. J Am Coll Cardiol,2003,41 (2) :275-279.
  • 9Inwaid DP, McdowaU A, Peters MJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation [ J ]. Circ Res, 2003,92 (9) :1041-1048.
  • 10Malarstig A ,Lindahl B, Wallentin L, et al. Soluble CD40L levels are regulated by the-3459 A > G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome [ J ]. Arterioscler Thromb Vasc Biol,2006,26 ( 7 ) : 1667 -1673.

同被引文献24

  • 1Ekelund U, Forberg JL. New methods for improved evaluation of patients with suspected acute coronary syndrome in the emergency department [J]. Emerg Med J, 2007,24(12) :811-814.
  • 2Williams BA, Wright RS, Murphy JG, et al. A new simplified immediate pro-gnostic risk score for patients with acute myocardial infarction [J]. Emerg Med J, 2006,23(3) : 186-192.
  • 3Gil Salles, Sergio Xavier, Andrea Sousa, et al. Prognostic value of QT interval parameters for mortality risk stratification in Chagas' Disease [J]. Circulation, 2003, 108(7):305-312.
  • 42005 American heart association guidelines for cardiopulrnonary resuscita-tion and emergency cardiovascular care: Stabilization of the patient with acute coronary syndromes[ J ]. Circulation, 2005,112 ( 12 ) : 89-110.
  • 5Cygakie wicz L, Wranicz JK, Bolinska H, et al. Relationship between heart rate turbulence and heart rate, heart rate Varibility, and number of Ventricular per-mater beats in coronary patients[ J]. Cardiovasc Electro- physiol, 2004,15 (7):731.
  • 6Patrick M. Cardiac markers: current technologies for their measurement at points of care[ J]. Near Patient Testing & Technology, 2006,3 (1): 38-46.
  • 7Keating L, Benger JR, Beetham R, et al, The prima study: presentation is-chaemia modified albumin in the emergency department [ J]. Emerg Med J, 2006, 23(10): 764-768.
  • 8Sinha MK, Roy D, Gaze I)C, et al. Role of ischemia modified albumin, a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndrome [J]. Emerg Med J, 2004,21 ( 1 ) : 29-34.
  • 9Collinson PO, Gaze DC, Bainbridge K, et al. Utility of admission cardiac tropo-nin and “Ischemia Modified Albumin” measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the e- mergency department [ J]. Emerg Med J,2006,23(4) :256-261.
  • 10Mad P, Domanovits H, Fazelnia C, et al. Human heart-type fatty acid binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction [ J ]. QJM, 2007,100(4 ) : 203-210.

引证文献1

二级引证文献6

心血管病学进展
2008年 第B05期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部